AtriCure/$ATRC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About AtriCure
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Ticker
$ATRC
Sector
Primary listing
Employees
1,300
Headquarters
Website
AtriCure Metrics
BasicAdvanced
$1.9B
-
-$0.77
-
-
Price and volume
Market cap
$1.9B
52-week high
$43.11
52-week low
$27.64
Average daily volume
369K
Financial strength
Current ratio
3.94
Quick ratio
2.67
Long term debt to equity
16.005
Total debt to equity
16.631
Interest coverage (TTM)
-5.32%
Profitability
EBITDA (TTM)
-14.065
Gross margin (TTM)
74.71%
Net profit margin (TTM)
-7.27%
Operating margin (TTM)
-6.82%
Effective tax rate (TTM)
-3.08%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
-3.53%
Return on equity (TTM)
-7.85%
Valuation
Price to revenue (TTM)
3.554
Price to book
4.02
Price to tangible book (TTM)
10.09
Price to free cash flow (TTM)
214.435
Free cash flow yield (TTM)
0.47%
Free cash flow per share (TTM)
0.175
Growth
Revenue change (TTM)
16.28%
Earnings per share change (TTM)
-11.03%
3-year revenue growth (CAGR)
18.19%
10-year revenue growth (CAGR)
15.54%
3-year earnings per share growth (CAGR)
-12.55%
10-year earnings per share growth (CAGR)
2.67%
What the Analysts think about AtriCure
Analyst ratings (Buy, Hold, Sell) for AtriCure stock.
Bulls say / Bears say
AtriCure posted 17.1% revenue growth year-over-year, reaching $136.1 million in Q2 2025, fueled by strong uptake across its Afib, LAA management, and pain management product lines (Nasdaq).
The company completed enrollment of all 6,500 patients in the pioneering LeAAPS clinical trial—the largest cardiac surgery device study ever—positioning its AtriClip platform for expanded approval in prophylactic stroke prevention (Business Wire).
After delivering strong Q2 results, management raised its full-year 2025 revenue guidance to $527 million–$533 million and increased its adjusted EBITDA outlook to $49 million–$52 million, signaling continued momentum in growth and profitability (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
AtriCure Financial Performance
Revenues and expenses
AtriCure Earnings Performance
Company profitability
AtriCure News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for AtriCure stock?
AtriCure (ATRC) has a market cap of $1.9B as of October 26, 2025.
What is the P/E ratio for AtriCure stock?
The price to earnings (P/E) ratio for AtriCure (ATRC) stock is 0 as of October 26, 2025.
Does AtriCure stock pay dividends?
No, AtriCure (ATRC) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next AtriCure dividend payment date?
AtriCure (ATRC) stock does not pay dividends to its shareholders.
What is the beta indicator for AtriCure?
AtriCure (ATRC) does not currently have a Beta indicator.